EFFICACY AND SAFETY OF THE DRUG UKRAIN IN CHRONIC HEPATITIS C PATIENTS

SOLOGUB T.V.¹, VOLTCHEK I.V.², KIVISEPP N.A.¹, GRIGORYEVA T.¹

1) Department of Infectious Diseases, St. Petersburg State Medical Academy, St. Petersburg, Russia.
2) Terra Medica Ltd., St. Petersburg, Russia.

Address for correspondence: Oleh Zahriychuk, Ukranian Anti-Cancer Institute, Margaretenstr. 7,1040 Vienna, Austria.

Summary: A total of 38 children, drawn from areas contaminated after the Chernobyl accident and suffering from recurrent bronchopulmonary pathology were included in the study To ascertain the effects of Ukrain, an anticancer and immunomodulating drug, it was administrated intravenously at a dose of 5 mg twice a week, up to a total dose of 35 mg. The control group included 10 children with the same pathology who received stan­dard anti-inflammatory therapy Compared with the control group, the group treated with Ukrain showed marked anti-inflammatory activity: rapid decrease in white blood cell count and blood sedimentation rate. The strong immunomodulatory effect of Ukrain was indicated through the improvement in specific humoral and cellular immunity: increases in the immunoglobulin G (IgG) level, the phagocytic activity of neutrophils, the number of total lymphocytes, T-lymphocytes and T-helpers, and the T-helpersIsuppressors ratio, in view of the positive results of this pilot study and the great importance of preventive and clinical investigation of this problem given the widespread distribution of nuclear power plants and of nuclear military equipment, further studies devoted to the impact of Ukrain on children with immune disorders from contaminated areas would be interesting and could lead to positive results.